Welcome to our dedicated page for Ipsen Sa news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen Sa stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen (ADR: IPSEY) reported strong H1 2026 results, with total sales of €2,190.2m, up 20.4% as reported and 23.5% at constant exchange rates, and portfolio-beyond-Somatuline sales growing 24.8% at CER. Core operating income rose 28.8% to €844.9m, lifting the core operating margin to 38.6%, up 2.5 points. IFRS net profit increased 20.0% to €402.6m, and free cash flow rose 34.9% to €651.7m, taking closing net cash to €1,004.9m.
On this basis, Ipsen upgraded its 2026 guidance to total sales growth >20% at constant currency (from >13%) and a core operating margin >37% (from >35%), while absorbing higher R&D and the dilutive impact of the Memo Therapeutics and Kartos Therapeutics acquisitions.
The company highlighted multiple pipeline advances, including positive Phase III results for Dysport in episodic and chronic migraine and for Iqirvo in primary biliary cholangitis, alongside the acquisition of Memo Therapeutics (potravitug) and an agreement to acquire Kartos Therapeutics (navtemadlin). Ipsen also reported that the Phase III BOLD trial of Bylvay in biliary atresia did not meet its primary endpoint.
Ipsen (ADR: IPSEY) announced the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately, replacing Ms. Witts, who stepped down following the 13 May 2026 Annual General Meeting.
According to Ipsen, Ms. Bradley brings over three decades of investment banking and international financial markets experience and more than ten years as a non-executive director. She has held senior roles at Merrill Lynch, Crédit Suisse and BNP Paribas, and has chaired audit committees at the UK FCA, Aberdeen, Groupe Peugeot and Worldpay.
The Board has appointed her Chair of the Audit Committee and a member of the Compensation Committee. Her mandate will be submitted for ratification at the next Annual Shareholders’ Meeting and, if approved, will run until the 2029 Annual Shareholders’ Meeting, completing Ms. Witts’ term. Ipsen’s Board remains composed of 14 directors, equally split between seven women and seven men, including four independent directors and two employee representatives.
Ipsen (OTC: IPSEY) reported weekly share buybacks under its Art 5 MAR programme for the period 20–24 July 2026. The company repurchased a total of 13,930 shares of instrument FR0010259150 across XPAR, CEUX and AQEU, at an overall weighted average price of 159.2669.
Summary not available.
Summary not available.
Summary not available.
Ipsen (Euronext: IPN; ADR: IPSEY) has announced its decision to request a re-examination of the CHMP's unfavorable opinion regarding the marketing authorization for palovarotene, intended for treating the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP) in the E.U. Currently, there are no disease-modifying treatments available for FOP in this region. The CHMP's decision was based on data from the MOVE trial, which assessed palovarotene's efficacy and safety. Ipsen remains committed to addressing the concerns raised and to providing innovative treatment options for the FOP community.
Ipsen announced promising results from the Phase III NAPOLI 3 trial for its investigational Onivyde regimen, aimed at treating previously untreated metastatic pancreatic ductal adenocarcinoma. The trial demonstrated a significant improvement in overall survival (11.1 months for Onivyde versus 9.2 months for nab-paclitaxel plus gemcitabine) and progression-free survival (7.4 months compared to 5.6 months). Ipsen plans to file a supplemental New Drug Application with the FDA. Despite a manageable safety profile, common adverse events included diarrhea and low blood cell counts.
Ipsen has announced a definitive merger agreement to acquire Albireo for $42.00 per share, plus a contingent value right of $10.00 pertaining to potential FDA approval for Bylvay in biliary atresia. This acquisition aims to enhance Ipsen's Rare Disease portfolio, particularly through the inclusion of Bylvay®, the first approved treatment for progressive familial intrahepatic cholestasis (PFIC). The total consideration for the acquisition amounts to approximately $952 million. The transaction is expected to close by the end of Q1 2023.